•  
  •  
  •  
  •  

2026-05-31 19:03:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Arkade Developers Reports Robust FY 26 Growth
  • Himatsingka Seide Ltd announces Q4, FY26 results
  • Refex Industries Ltd receives order worth Rs. 36.91 crores
  • Siyaram Recycling Industries Ltd receives order worth Rs. 1.97 crore
  • EP Biocomposites Limited Reports Strong FY26 Results

Keywords Selected:  MarksansPharma

Stock Report

  • Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • Relonchem Limited receives Marketing Authorization for its two products
  • Marksans Pharma Reports Record Q2 FY26 Performance
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution
  • Relonchem Ltd receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution
  • USFDA inspection at manufacturing facility of Marksans Pharma's subsidiary Time-Cap Laboratories, Inc.
  • Marksans Pharma Ltd's manufacturing facility at Verna, Goa approved by Australian TG
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • Relonchem Ltd receives Marketing Authorization for Ibuprofen and Paracetamol tablets
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Marksans Pharma Limited updates on USFDA inspection at Verna, Goa manufacturing facility
  • Marksans highest ever quarter revenue at Rs 586 crore grew by 22% YoY, and EBITDA at Rs 133 crore grew by 74 % YoY
  • Marksans Pharma Ltd announces US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
  • Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
  • Marksans announces completion of US FDA Post-marketing Adverse Drug Experience inspection
  • Marksans announces FDA approval of OTC equivalent of Advil Dual Action Tablets

Latest Post

  • Arkade Developers Reports Robust FY 26 Growth
  • Himatsingka Seide Ltd announces Q4, FY26 results
  • Refex Industries Ltd receives order worth Rs. 36.91 crores
  • Siyaram Recycling Industries Ltd receives order worth Rs. 1.97 crore
  • EP Biocomposites Limited Reports Strong FY26 Results


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025